Health Editor’s Note: It is very important that we are able to vaccinate children under 18 (Pfizer vaccine is approved for use in those 16-years old and up). Getting a safe, effective vaccine into children is paramount to protecting the entire population of the world. Children can get back to learning and living a normal life of a child…..Carol
by Caitlin O’Kane/CBS news
“It is humbling to know that 53 million doses have been administered to people in the U.S.,” Stéphane Bancel, chief executive officer of Moderna, said in a statement. “We are encouraged by the primary analysis of the Phase 3 COVE study of mRNA-1273 in adults ages 18 and above and this pediatric study will help us assess the potential safety and immunogenicity of our COVID-19 vaccine candidate in this important younger age population.”
Moderna plans to enroll approximately 6,750 pediatric participants in the U.S. and Canada in the two-part study. In part 1, each participant ages 2 years to less than 12 years may receive one of two dose levels, while each participant ages six months to less than 2 years may receive one of three dose levels.
Following analysis, researchers will determine which dose will be used in part 2 of the study, which involves a placebo for comparison.
Children participating in the study will be followed for 12 months after receiving the second vaccination…… Read More: